Literature DB >> 17727912

Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus.

Jason C Steel1, Brian J Morrison, Poonam Mannan, Mones S Abu-Asab, Oliver Wildner, Brian K Miles, Kevin C Yim, Vijay Ramanan, Gregory A Prince, John C Morris.   

Abstract

Oncolytic adenoviruses as a treatment for cancer have demonstrated limited clinical activity. Contributing to this may be the relevance of preclinical animal models used to study these agents. Syngeneic mouse tumor models are generally non-permissive for adenoviral replication, whereas human tumor xenograft models exhibit attenuated immune responses to the vector. The cotton rat (Sigmodon hispidus) is susceptible to human adenovirus infection, permissive for viral replication and exhibits similar inflammatory pathology to humans with adenovirus replicating in the lungs, respiratory passages and cornea. We evaluated three transplantable tumorigenic cotton rat cell lines, CCRT, LCRT and VCRT as models for the study of oncolytic adenoviruses. All three cells lines were readily infected with adenovirus type-5-based vectors and exhibited high levels of transgene expression. The cell lines supported viral replication demonstrated by the induction of cytopathogenic effect (CPE) in tissue culture, increase in virus particle numbers and assembly of virions seen on transmission electron microscopy. In vivo, LCRT and VCRT tumors demonstrated delayed growth after injection with replicating adenovirus. No in vivo antitumor activity was seen in CCRT tumors despite in vitro oncolysis. Adenovirus was also rapidly cleared from the CCRT tumors compared to LCRT and VCRT tumors. The effect observed with the different cotton rat tumor cell lines mimics the variable results of human clinical trials highlighting the potential relevance of this model for assessing the activity and toxicity of oncolytic adenoviruses.

Entities:  

Mesh:

Year:  2007        PMID: 17727912      PMCID: PMC2104792          DOI: 10.1016/j.virol.2007.07.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  37 in total

1.  Manipulation of the cytoplasmic and transmembrane domains alters cell surface levels of the coxsackie-adenovirus receptor and changes the efficiency of adenovirus infection.

Authors:  W van't Hof; R G Crystal
Journal:  Hum Gene Ther       Date:  2001-01-01       Impact factor: 5.695

2.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.

Authors:  Y Zhang; N Chirmule; G P Gao; R Qian; M Croyle; B Joshi; J Tazelaar; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

3.  Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.

Authors:  Christian Jogler; Dennis Hoffmann; Dirk Theegarten; Thomas Grunwald; Klaus Uberla; Oliver Wildner
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 4.  Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.

Authors:  D Kirn
Journal:  Expert Opin Biol Ther       Date:  2001-05       Impact factor: 4.388

5.  A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.

Authors:  R Benjamin; L Helman; P Meyers; G Reaman
Journal:  Hum Gene Ther       Date:  2001-08-10       Impact factor: 5.695

6.  Subcutaneous Administration of a Replication-Competent Adenovirus Expressing HSV-tk to Cotton Rats: Dissemination, Persistence, Shedding, and Pathogenicity.

Authors:  Oliver Wildner; John C Morris
Journal:  Hum Gene Ther       Date:  2002-01-01       Impact factor: 5.695

7.  Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma.

Authors:  Nagy Habib; Hosny Salama; Ahmed Abd El Latif Abu Median; Ilia Isac Anis; Rasha Ahmed Abd Al Aziz; Catherine Sarraf; Ragai Mitry; Roman Havlik; Prem Seth; Jack Hartwigsen; Reva Bhushan; Joanna Nicholls; Steen Jensen
Journal:  Cancer Gene Ther       Date:  2002-03       Impact factor: 5.987

8.  A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.

Authors:  T L DeWeese; H van der Poel; S Li; B Mikhak; R Drew; M Goemann; U Hamper; R DeJong; N Detorie; R Rodriguez; T Haulk; A M DeMarzo; S Piantadosi; D C Yu; Y Chen; D R Henderson; M A Carducci; W G Nelson; J W Simons
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

9.  Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.

Authors:  Svend O Freytag; Mark Khil; Hans Stricker; James Peabody; Mani Menon; Mariza DePeralta-Venturina; Daniel Nafziger; Jan Pegg; Dell Paielli; Steve Brown; Ken Barton; Mei Lu; Estuardo Aguilar-Cordova; Jae Ho Kim
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 10.  Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases.

Authors:  Stefan Niewiesk; Gregory Prince
Journal:  Lab Anim       Date:  2002-10       Impact factor: 2.471

View more
  11 in total

1.  Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodies.

Authors:  Dhohyung Kim; Luis Martinez-Sobrido; Changsun Choi; Natasha Petroff; Adolfo García-Sastre; Stefan Niewiesk; Thomas Carsillo
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

2.  Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.

Authors:  Breanne Cuddington; Meghan Verschoor; Karen Mossman
Journal:  J Vis Exp       Date:  2014-11-24       Impact factor: 1.355

Review 3.  Armed replicating adenoviruses for cancer virotherapy.

Authors:  J J Cody; J T Douglas
Journal:  Cancer Gene Ther       Date:  2009-02-06       Impact factor: 5.987

4.  A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.

Authors:  L Zhang; F Hedjran; C Larson; G L Perez; T Reid
Journal:  Cancer Gene Ther       Date:  2014-12-19       Impact factor: 5.987

5.  Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses.

Authors:  Catherine M Crosby; William E Matchett; Stephanie S Anguiano-Zarate; Christopher A Parks; Eric A Weaver; Larry R Pease; Richard J Webby; Michael A Barry
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

6.  An Oncolytic Adenovirus Vector Expressing p14 FAST Protein Induces Widespread Syncytium Formation and Reduces Tumor Growth Rate In Vivo.

Authors:  Josh Del Papa; Julia Petryk; John C Bell; Robin J Parks
Journal:  Mol Ther Oncolytics       Date:  2019-05-15       Impact factor: 7.200

7.  Rodents Versus Pig Model for Assessing the Performance of Serotype Chimeric Ad5/3 Oncolytic Adenoviruses.

Authors:  Lisa Koodie; Matthew G Robertson; Malavika Chandrashekar; George Ruth; Michele Dunning; Richard W Bianco; Julia Davydova
Journal:  Cancers (Basel)       Date:  2019-02-08       Impact factor: 6.639

8.  Chorioallantoic Membrane Tumor Model for Evaluating Oncolytic Viruses.

Authors:  Lea Krutzke; Ellen Allmendinger; Katja Hirt; Stefan Kochanek
Journal:  Hum Gene Ther       Date:  2020-08-17       Impact factor: 5.695

9.  Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.

Authors:  Janet Lei; Egon J Jacobus; William K Taverner; Kerry D Fisher; Silvio Hemmi; Katy West; Lorna Slater; Fred Lilley; Alice Brown; Brian Champion; Margaret R Duffy; Len W Seymour
Journal:  J Immunother Cancer       Date:  2018-06-13       Impact factor: 13.751

Review 10.  Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model.

Authors:  Carla De Giovanni; Giordano Nicoletti; Lorena Landuzzi; Arianna Palladini; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.